JP2000512980A - 腫瘍のｉｌ―１２遺伝子治療 - Google Patents
腫瘍のｉｌ―１２遺伝子治療Info
- Publication number
- JP2000512980A JP2000512980A JP10500803A JP50080398A JP2000512980A JP 2000512980 A JP2000512980 A JP 2000512980A JP 10500803 A JP10500803 A JP 10500803A JP 50080398 A JP50080398 A JP 50080398A JP 2000512980 A JP2000512980 A JP 2000512980A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- cells
- gene
- subunit
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 123
- 238000001415 gene therapy Methods 0.000 title abstract description 35
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 210000004027 cell Anatomy 0.000 claims description 45
- 239000002245 particle Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 12
- 230000002068 genetic effect Effects 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 4
- 210000001339 epidermal cell Anatomy 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 abstract description 4
- 238000013459 approach Methods 0.000 abstract description 4
- 102000004127 Cytokines Human genes 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 60
- 108020004414 DNA Proteins 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 25
- 108090000663 Annexin A1 Proteins 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- 230000004614 tumor growth Effects 0.000 description 14
- 102400000124 Cyclin-dependent kinase 5 activator 1, p35 Human genes 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 9
- 239000010931 gold Substances 0.000 description 9
- 229910052737 gold Inorganic materials 0.000 description 9
- 238000002513 implantation Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 102000048850 Neoplasm Genes Human genes 0.000 description 3
- 108700019961 Neoplasm Genes Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 108010001267 Protein Subunits Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000019734 interleukin-12 production Effects 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 201000006512 mast cell neoplasm Diseases 0.000 description 2
- 208000006971 mastocytoma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 description 1
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 description 1
- 101000583935 Homo sapiens CDK-activating kinase assembly factor MAT1 Proteins 0.000 description 1
- 101000912009 Homo sapiens Cyclin-dependent kinase 5 activator 1 Proteins 0.000 description 1
- 101001038346 Homo sapiens GTP cyclohydrolase 1 feedback regulatory protein Proteins 0.000 description 1
- 101001090483 Homo sapiens Glutathione S-transferase LANCL1 Proteins 0.000 description 1
- 101000980900 Homo sapiens Sororin Proteins 0.000 description 1
- 101000808126 Homo sapiens Uroplakin-3b Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 229920006355 Tefzel Polymers 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical compound C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000048091 human CDCA5 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000009463 immunological memory response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000027909 protein adenylylation Effects 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/659,206 | 1996-06-05 | ||
| US08/659,206 US5922685A (en) | 1996-06-05 | 1996-06-05 | IL-12 gene therapy of tumors |
| PCT/US1997/009591 WO1997046263A1 (en) | 1996-06-05 | 1997-06-04 | Il-12 gene therapy of tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000512980A true JP2000512980A (ja) | 2000-10-03 |
| JP2000512980A5 JP2000512980A5 (enExample) | 2005-01-13 |
Family
ID=24644498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10500803A Ceased JP2000512980A (ja) | 1996-06-05 | 1997-06-04 | 腫瘍のｉｌ―１２遺伝子治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5922685A (enExample) |
| EP (1) | EP0963207B1 (enExample) |
| JP (1) | JP2000512980A (enExample) |
| DE (1) | DE69735643T2 (enExample) |
| ES (1) | ES2262180T3 (enExample) |
| WO (1) | WO1997046263A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998041229A1 (en) * | 1997-03-19 | 1998-09-24 | F. Hoffmann-La Roche Ag | USE OF IL-12p40 AS IMMUNOSTIMULANT |
| ES2590912T3 (es) | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| ES2267263T3 (es) * | 1998-04-15 | 2007-03-01 | Emd Lexigen Research Center Corp. | Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo. |
| AU761520B2 (en) * | 1998-09-15 | 2003-06-05 | Genetics Institute, Llc | Treatment of Kaposi's Sarcoma with IL-12 |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| US20030190305A1 (en) * | 1999-09-15 | 2003-10-09 | Wyeth And National Institutes Of Health | Treatment of Kaposi's sarcoma with IL-12 |
| ATE285806T1 (de) | 1999-10-11 | 2005-01-15 | Felton International Inc | Universelle antiinfektionsschutzvorrichtung für nadellose injektoren |
| US7074210B2 (en) * | 1999-10-11 | 2006-07-11 | Felton International, Inc. | Universal protector cap with auto-disable features for needle-free injectors |
| CN1182874C (zh) * | 1999-10-29 | 2005-01-05 | 安增子摩祺株式会社 | 糖尿病性局部缺血疾病的基因治疗制剂 |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| US7887506B1 (en) | 1999-11-23 | 2011-02-15 | Pulse Needlefree Systems, Inc. | Safety mechanism to prevent accidental patient injection and methods of same |
| US6770054B1 (en) | 1999-11-23 | 2004-08-03 | Felton International, Inc. | Injector assembly with driving means and locking means |
| US7115712B1 (en) | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| US20040213798A1 (en) * | 2000-06-08 | 2004-10-28 | Powderject Vaccines, Inc. | Spray-dried alum compositions |
| US20020120228A1 (en) * | 2000-06-08 | 2002-08-29 | Yuh-Fun Maa | Powder compositions |
| KR20030064275A (ko) * | 2000-06-29 | 2003-07-31 | 메르크 파텐트 게엠베하 | 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강 |
| US20020086036A1 (en) | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
| US7255865B2 (en) * | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
| RU2003129528A (ru) * | 2001-03-07 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела |
| WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| EP1383785B1 (en) | 2001-05-03 | 2011-03-16 | Merck Patent GmbH | Recombinant tumor specific antibody and use thereof |
| CA2349506C (en) * | 2001-06-14 | 2009-12-08 | Duke University | A method for selective expression of therapeutic genes by hyperthermia |
| DK1454138T3 (da) * | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| WO2004055056A1 (en) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| EP1702069A2 (en) * | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| PL1966238T3 (pl) | 2005-12-30 | 2012-09-28 | Merck Patent Gmbh | Warianty interleukiny-12p40 o polepszonej stabilności |
| US7833754B2 (en) * | 2006-01-13 | 2010-11-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IL-12 for expression in mammalian cell |
| BRPI0818287A2 (pt) * | 2007-10-08 | 2015-11-03 | Intrexon Corp | células dendríticas manipuladas e usos para o tratamento do câncer. |
| RU2573912C2 (ru) | 2008-10-08 | 2016-01-27 | Интрексон Корпорейшн | Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения |
| WO2010126766A1 (en) * | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| US20110014228A1 (en) * | 2009-06-15 | 2011-01-20 | New York University | Il23 modified viral vector for recombinant vaccines and tumor treatment |
| SI3458083T1 (sl) | 2016-05-18 | 2023-03-31 | Modernatx, Inc. | Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba |
| JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5015580A (en) * | 1987-07-29 | 1991-05-14 | Agracetus | Particle-mediated transformation of soybean plants and lines |
| US5149655A (en) * | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
| DK0690732T3 (da) * | 1994-01-21 | 2003-05-19 | Powderject Vaccines Inc | Gasdrevet genindførselsinstrument |
| JP2001503258A (ja) * | 1996-10-18 | 2001-03-13 | バレンティス・インコーポレーテッド | 遺伝子発現および搬送系および用途 |
-
1996
- 1996-06-05 US US08/659,206 patent/US5922685A/en not_active Expired - Fee Related
-
1997
- 1997-06-04 DE DE69735643T patent/DE69735643T2/de not_active Expired - Fee Related
- 1997-06-04 WO PCT/US1997/009591 patent/WO1997046263A1/en not_active Ceased
- 1997-06-04 ES ES97927949T patent/ES2262180T3/es not_active Expired - Lifetime
- 1997-06-04 JP JP10500803A patent/JP2000512980A/ja not_active Ceased
- 1997-06-04 EP EP97927949A patent/EP0963207B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US5922685A (en) | 1999-07-13 |
| HK1024622A1 (en) | 2000-10-20 |
| EP0963207A4 (en) | 2003-01-22 |
| WO1997046263A1 (en) | 1997-12-11 |
| ES2262180T3 (es) | 2006-11-16 |
| DE69735643D1 (de) | 2006-05-18 |
| DE69735643T2 (de) | 2006-12-14 |
| EP0963207B1 (en) | 2006-04-05 |
| EP0963207A1 (en) | 1999-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000512980A (ja) | 腫瘍のｉｌ―１２遺伝子治療 | |
| US20210062218A1 (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| Iwasaki et al. | Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines | |
| US7446185B2 (en) | Her2/neu target antigen and use of same to stimulate an immune response | |
| Tamura et al. | Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer | |
| TW202146435A (zh) | 含有病原性抗原及免疫刺激物之組合物 | |
| Shi et al. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF | |
| HUE027617T2 (en) | Universal tumor cell vaccine for therapeutic and prophylactic use | |
| CA2490863A1 (en) | Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase | |
| US20210369824A1 (en) | Methods and materials for treating cancer | |
| JPH10505339A (ja) | 腫瘍疾患の治療のための生ワクチン | |
| US20070275049A1 (en) | Anti-tumor molecular vacine and method of making thereof | |
| Yang et al. | Developing particle-mediated gene-transfer technology for research into gene therapy of cancer | |
| Reali et al. | Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms | |
| Davidoff et al. | Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12 | |
| Shawler et al. | Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma | |
| EP2147682B1 (en) | Vaccination with immuno-isolated cells producing an immunomodulator | |
| CN102086453A (zh) | 以粘蛋白1和生存素为靶点的肿瘤dna疫苗及病毒载体疫苗 | |
| WO2025190157A1 (zh) | 一种治疗犬黑色素瘤的环状rna疫苗 | |
| KR20070068398A (ko) | 재조합 마이코박테리움의 조합물 및 백신과 같은 생물학적활성제 | |
| Qian et al. | Efficient tumor regression induced by genetically engineered tumor cells secreting interleukin-2 and membrane-expressing allogeneic MHC class I antigen | |
| CN117693357A (zh) | 基于诱导多能干细胞的癌症疫苗 | |
| HK1024622B (en) | Il 12 for the gene therapy of tumours | |
| Dunussi-Joannopoulos et al. | Interleukin-12 gene therapy vaccines: directing the immune system against minimal residual leukemia | |
| WO2001078769A2 (en) | Regulation of systemic immune responses utilizing soluble cd40 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040528 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040528 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070821 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071120 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080221 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080304 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080513 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081007 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081125 |